HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trialAntonio Llombart‐Cussac, Aleix Prat, Rafael López‐López et al.|The Lancet Oncology|2017Cited by 340
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Tomás Pascual et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast CancerJosé Baselga, Frederico Costa, Henri Roché et al.|Journal of Clinical Oncology|2012Cited by 163
PALBOCOMP: Retrospective observational analysis of palbociclib treatment in patients with advanced breast cancer within a compassionate use program in SpainLuís Manso, Fernando Moreno, Begoña Bermejo et al.|Annals of Oncology|2019Cited by 0